Defiance Next Gen Altered Experience ETF (PSY) Research
This fund is designed to mirror a systematically constructed index. This index evaluates the performance of companies engaged in specific, legally authorized activities, always in adherence to national laws. These activities encompass the fields of medical psychedelics, therapeutic cannabis, cannabis-derived pharmaceuticals, cannabidiol (CBD) derivatives, and ketamine. To achieve its financial goals, the fund utilizes a full replication approach, meaning it directly invests in all the constituent securities of the underlying index, striving to maintain their proportional weightings. It functions as a non-diversified investment product.
Market snapshot
- Symbol
- PSY
- Price
- $5.90
- Day change
- -0.51%
- Market cap
- $4.7M
- 52-week range
- 5.84-5.91
- Sector
- Financial Services
- Industry
- Asset Management
Peer companies
- iPath Series B Bloomberg Cotton Subindex Total Return ETN (BAL)
- Roundhill BIG Bank ETF (BIGB)
- ProShares Short Oil & Gas (DDG)
- DeltaShares S&P 400 Managed Risk ETF (DMRM)
- FlexShares ESG & Climate Emerging Markets Core Index Fund (FEEM)
- AGFiQ U.S. Market Neutral Momentum Fund (MOM)
- IQ Clean Oceans ETF (OCEN)
- Global X Solar ETF (RAYS)
Recent insider activity
- ROBARDS KAREN P — J-Other (690 shares) on 2012-12-10
- KESTER W CARL — J-Other (100 shares) on 2012-12-10
- Harris Jerrold B — J-Other (161 shares) on 2012-12-10
- CAVANAGH RICHARD — J-Other (100 shares) on 2012-12-10
- GABBAY HENRY — J-Other (100 shares) on 2012-12-10
Open Defiance Next Gen Altered Experience ETF (PSY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.